The UK National Institute for
Health and Care Excellence (NICE)
has given the go ahead for afatinib
(Giotrif from Boehringer Ingelheim)
indicated for lung cancer to be paid
for by the NHS, and people newly
diagnosed with the blood cancer
multiple myeloma would now be
guaranteed access to Bortezomib
(Velcade by Janssen).The above article was sent to subscribers in Pharmacy Daily's issue from 24 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Apr 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.